Fused Pyrimidine-Based Drug Discovery

Dr. Raj Kumar, FRSC, is currently working as Dean of School of Health Sciences, and a Professor at the Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, India. He obtained his Ph.D. in Medicinal Chemistry (2007) from NIPER, Mohali, India and completed his postdoctoral fellowship (2007-2008) at the University of Maryland Baltimore County (UMBC), Maryland where he co-invented a fused heterocycle RK-33 (Raj Kumar-33) molecule for the treatment of Lung Cancer. Dr. Kumar has published more than 90 peer-reviewed research papers (h index = 33; Scopus) in leading Medicinal/Organic/Pharmaceutical Chemistry Journals with a cumulative impact factor > 300. Dr. Kumar has been featured in the list of top 2% international scientists “Updated Science-wide Database of Stanford Citation Indicators” released by Stanford University, USA and published by Elsevier BV on 19th October 2021. His research interests focus on the design and synthesis of novel fused heterocycles of biological importance.

1. Introduction 2. FDA Approved Fused Pyrimidine-Based Drugs 3. Naturally occurring fused pyrimidine derivatives and Medicinal Attributes 4. Five-Membered Ring Fused Pyrimidine-Based Derivatives and Biological Properties 5. FDA approved Five-Membered Ring Fused Pyrimidine-Based Derivatives and Biological Properties 6. Benzene Fused Pyrimidine-Based Derivatives and their Biological Properties 7. Six-Membered Ring (with N, O or S) Fused Pyrimidine-Based Derivatives and Biological Properties 8. FDA approved Six-Membered Ring Fused Pyrimidine-Based Derivatives 9. Seven-Membered Ring Fused Pyrimidine-Based Derivatives and Biological Properties 10. Eight-Membered Fused Pyrimidine Derivatives and Biological Properties 11. Molecular Modeling Studies of Fused Pyrimidine Derivatives at various receptors